Masimo/$MASI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Masimo
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
Ticker
$MASI
Sector
Primary listing
Employees
3,600
Headquarters
Website
Masimo Metrics
BasicAdvanced
$7.6B
-
-$10.55
1.26
-
Price and volume
Market cap
$7.6B
Beta
1.26
52-week high
$194.88
52-week low
$133.70
Average daily volume
727K
Financial strength
Current ratio
2.836
Quick ratio
1.627
Long term debt to equity
69.025
Total debt to equity
69.025
Interest coverage (TTM)
2.83%
Profitability
EBITDA (TTM)
197.2
Gross margin (TTM)
49.33%
Net profit margin (TTM)
-26.10%
Operating margin (TTM)
5.66%
Effective tax rate (TTM)
-15.36%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
3.14%
Return on equity (TTM)
-21.14%
Valuation
Price to revenue (TTM)
3.516
Price to book
9.48
Price to tangible book (TTM)
11.76
Price to free cash flow (TTM)
45.748
Free cash flow yield (TTM)
2.19%
Free cash flow per share (TTM)
3.107
Growth
Revenue change (TTM)
25.62%
Earnings per share change (TTM)
-825.99%
3-year revenue growth (CAGR)
7.71%
10-year revenue growth (CAGR)
13.35%
3-year earnings per share growth (CAGR)
51.30%
10-year earnings per share growth (CAGR)
21.59%
What the Analysts think about Masimo
Analyst ratings (Buy, Hold, Sell) for Masimo stock.
Bulls say / Bears say
Masimo’s lawsuit against U.S. Customs over the agency’s decision to permit Apple Watch imports featuring blood-oxygen monitoring introduces legal uncertainty and potential litigation costs that could weigh on the company’s financials and distract management. (Reuters)
The U.S. Customs approval for Apple to re-enable the blood-oxygen feature on Apple Watches illustrates Masimo’s vulnerability as competitors bypass its patents through regulatory channels, potentially eroding its market exclusivity and future sensor revenues. (Reuters)
Apple’s appeal of the 2023 ITC ruling at the U.S. appeals court highlights prolonged litigation that could delay or weaken Masimo’s patent enforcement efforts, increasing legal expenses and the risk of an adverse outcome. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
Masimo Financial Performance
Revenues and expenses
Masimo Earnings Performance
Company profitability
Masimo News
AllArticlesVideos
HARMAN Completes Sound United Acquisition to Expand Premium Audio Leadership
Business Wire1 month ago
Masimo Completes Sale of Consumer Audio Business to HARMAN International
Business Wire1 month ago
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Masimo stock?
Masimo (MASI) has a market cap of $7.6B as of November 06, 2025.
What is the P/E ratio for Masimo stock?
The price to earnings (P/E) ratio for Masimo (MASI) stock is 0 as of November 06, 2025.
Does Masimo stock pay dividends?
No, Masimo (MASI) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Masimo dividend payment date?
Masimo (MASI) stock does not pay dividends to its shareholders.
What is the beta indicator for Masimo?
Masimo (MASI) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.